These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 31383555)

  • 21. Acceptability and feasibility of mifepristone-misoprostol for menstrual regulation in Bangladesh.
    Alam A; Bracken H; Johnston HB; Raghavan S; Islam N; Winikoff B; Reichenbach L
    Int Perspect Sex Reprod Health; 2013 Jun; 39(2):79-87. PubMed ID: 23895884
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Second trimester medical abortion with mifepristone followed by unlimited dosing of buccal misoprostol in Armenia.
    Louie KS; Chong E; Tsereteli T; Avagyan G; Abrahamyan R; Winikoff B
    Eur J Contracept Reprod Health Care; 2017 Feb; 22(1):76-80. PubMed ID: 27871191
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Evolution of Medication Abortion Care: Using Science to Achieve Quality.
    Dalton VK; Wallett S
    Obstet Gynecol; 2015 Jul; 126(1):3-4. PubMed ID: 26241249
    [No Abstract]   [Full Text] [Related]  

  • 24. Vaginal misoprostol administered 1, 2, or 3 days after mifepristone for early medical abortion: A randomized trial.
    Schaff EA; Fielding SL; Westhoff C; Ellertson C; Eisinger SH; Stadalius LS; Fuller L
    JAMA; 2000 Oct; 284(15):1948-53. PubMed ID: 11035891
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acceptability and feasibility of medical abortion with mifepristone and misoprostol in Nigeria.
    Okonofua F; Shittu O; Shochet T; Diop A; Winikoff B
    Int J Gynaecol Obstet; 2014 Apr; 125(1):49-52. PubMed ID: 24507887
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacy workers' knowledge and provision of abortifacients in Ho Chi Minh City, Vietnam.
    Ngo TD; Park MH; Nguyen TH
    Int J Gynaecol Obstet; 2012 May; 117(2):187-8. PubMed ID: 22342054
    [No Abstract]   [Full Text] [Related]  

  • 27. Landscape assessment of the availability of medical abortion medicines in India.
    Karna P; Sharma KA; Grossman A; Gupta M; Chatterjee T; Williams N; Prata N; Sorhaindo A; Läser L; Rehnström Loi U; Ganatra B; Chaudhary P
    Reprod Health; 2024 Jun; 20(Suppl 1):193. PubMed ID: 38840263
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mifepristone+misoprostol vs. misoprostol alone for early medical abortion.
    Ngo TD; Park MH
    Contraception; 2012 Feb; 85(2):219; author reply 219-20. PubMed ID: 22067779
    [No Abstract]   [Full Text] [Related]  

  • 29. The costs and cost effectiveness of providing second-trimester medical and surgical safe abortion services in Western Cape Province, South Africa.
    Lince-Deroche N; Constant D; Harries J; Kluge J; Blanchard K; Sinanovic E; Grossman D
    PLoS One; 2018; 13(6):e0197485. PubMed ID: 29953434
    [TBL] [Abstract][Full Text] [Related]  

  • 30. First-trimester medical abortion with mifepristone 200 mg and misoprostol: a systematic review.
    Raymond EG; Shannon C; Weaver MA; Winikoff B
    Contraception; 2013 Jan; 87(1):26-37. PubMed ID: 22898359
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Self-administration of vaginal misoprostol after mifepristone for termination of pregnancy: patient acceptability.
    Kiran U; Amin P; Penketh RJ
    J Obstet Gynaecol; 2006 Oct; 26(7):679-81. PubMed ID: 17071439
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Providing medication abortion information to diverse communities: use patterns of a multilingual web site.
    Foster AM; Wynn L; Rouhana A; Diaz-Olavarrieta C; Schaffer K; Trussell J
    Contraception; 2006 Sep; 74(3):264-71. PubMed ID: 16904422
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Simultaneous Administration Compared With a 24-Hour Mifepristone-Misoprostol Interval in Second-Trimester Abortion: A Randomized Controlled Trial.
    Abbas DF; Blum J; Ngoc NT; Nga NT; Chi HT; Martin R; Winikoff B
    Obstet Gynecol; 2016 Nov; 128(5):1077-1083. PubMed ID: 27741182
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A review of evidence for safe abortion care.
    Kapp N; Whyte P; Tang J; Jackson E; Brahmi D
    Contraception; 2013 Sep; 88(3):350-63. PubMed ID: 23261233
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mifepristone-misoprostol abortion: a trial in rural and urban Maharashtra, India.
    Coyaji K; Elul B; Krishna U; Otiv S; Ambardekar S; Bopardikar A; Raote V; Ellertson C; Winikoff B
    Contraception; 2002 Jul; 66(1):33-40. PubMed ID: 12169379
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Outpatient medical abortion is safe and effective through 70 days gestation.
    Abbas D; Chong E; Raymond EG
    Contraception; 2015 Sep; 92(3):197-9. PubMed ID: 26118638
    [TBL] [Abstract][Full Text] [Related]  

  • 37. If we can do it for misoprostol, why not for mifepristone? The case for taking mifepristone out of the office in medical abortion.
    Gold M; Chong E
    Contraception; 2015 Sep; 92(3):194-6. PubMed ID: 26093187
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of mifepristone and buccal misoprostol versus buccal misoprostol alone for medical abortion.
    Dahiya K; Ahuja K; Dhingra A; Duhan N; Nanda S
    Arch Gynecol Obstet; 2012 Apr; 285(4):1055-8. PubMed ID: 22009509
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Minimal effective dose of mifepristone for medical abortion.
    Kapoor G; Salhan S; Sarda N; Aggarwal D
    J Indian Med Assoc; 2014 Feb; 112(2):96-9. PubMed ID: 25935963
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Self-administration of misoprostol for termination of pregnancy: safety and efficacy.
    Kiran U; Amin P; Penketh RJ
    J Obstet Gynaecol; 2004 Feb; 24(2):155-6. PubMed ID: 14766452
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.